Sarepta therapeutics provides program update for srp-9001

Sarepta therapeutics provides program update for srp-9001, its investigational gene therapy for the treatment of duchenne muscular dystrophy.completed a type c 'written response only' meeting with office of tissues and advanced therapies.completed a type c 'written response only' meeting to obtain otat's concurrence on commencement of trial for srp-9001.has several existing assays and data that it believes could be employed in response to otat's request.otat requested that co utilize additional potency assay for release of srp-9001 commercial process material prior to dosing in study.additional dialogue with agency is required to determine acceptability of potency assay approach.
SRPT Ratings Summary
SRPT Quant Ranking